Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HROW

Harrow Inc

Mar 13 • 04:00PM ET

34.10

-1.46 -4.11 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: OCUL EYPT PRPH AKTX ALDX EDIT QURE TTOO CRSP BNGO

| Held by: VTI IWM VXF IWO VTWO SCHA XPH VHT FYC IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.16	Insider Own	16.25%	Shs Outstand	37.23M	Perf Week	-6.19%
Market Cap	1.27B	Forward P/E	12.33	EPS next Y	2.77	Insider Trans	-3.56%	Shs Float	31.18M	Perf Month	-29.92%
Enterprise Value	1.45B	PEG	-	EPS next Q	-0.22	Inst Own	59.62%	Short Float	17.26%	Perf Quarter	-32.07%
Income	-5.14M	P/S	4.66	EPS this Y	647.32%	Inst Trans	3.74%	Short Ratio	7.48	Perf Half Y	-13.56%
Sales	272.30M	P/B	24.21	EPS next Y	261.07%	ROA	-1.29%	Short Interest	5.38M	Perf YTD	-30.41%
Book/sh	1.41	P/C	17.41	EPS next 5Y	-	ROE	-8.42%	52W High	54.85 -37.83%	Perf Year	53.33%
Cash/sh	1.96	P/FCF	29.54	EPS past 3/5Y	35.17% -1.53%	ROIC	-1.69%	52W Low	20.85 63.55%	Perf 3Y	86.85%
Dividend Est.	-	EV/EBITDA	24.78	Sales past 3/5Y	45.39% 40.99%	Gross Margin	75.05%	Volatility	5.53% 6.25%	Perf 5Y	314.84%
Dividend TTM	-	EV/Sales	5.32	EPS Y/Y TTM	68.55%	Oper. Margin	14.31%	ATR (14)	2.93	Perf 10Y	744.06%
Dividend Ex-Date	-	Quick Ratio	2.06	Sales Y/Y TTM	36.41%	Profit Margin	-1.89%	RSI (14)	28.50	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.20	EPS Q/Q	-5.97%	SMA20	-24.11%	Beta	0.24	Target Price	69.12
Payout	-	Debt/Eq	4.80	Sales Q/Q	33.31%	SMA50	-26.34%	Rel Volume	1.64	Prev Close	35.56
Employees	373	LT Debt/Eq	4.79	Earnings	Mar 02 AMC	SMA200	-15.36%	Avg Volume	719.20K	Price	34.10
IPO	Apr 24, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-53.78% -1.00%	Trades		Volume	1,180,994	Change	-4.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight	$76
Jun-12-25	Initiated	BTIG Research	Buy	$62
Jun-10-25	Initiated	William Blair	Outperform
Feb-06-25	Initiated	H.C. Wainwright	Buy	$57
Dec-04-24	Reiterated	B. Riley Securities	Buy	$73 → $69
Apr-11-24	Initiated	Craig Hallum	Buy	$24
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Mar-09-26 09:03PM	Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions (GuruFocus.com)
Mar-04-26 07:00AM	Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference (GlobeNewswire)
Mar-03-26 04:14PM	Why Harrow, An IBD 50 Stock Up 32% Since January, Just Crashed (Investor's Business Daily) -27.96%
11:18AM	Harrow Q4 Earnings Call Highlights (MarketBeat)
08:11AM	Why Is Eye-Disease-Focused Harrow Stock Falling Today? (Benzinga)
07:00AM	Loading…
07:00AM	Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication (GlobeNewswire)
Mar-02-26 06:00PM	Harrow (HROW) Misses Q4 Earnings Estimates (Zacks)
05:08PM	Harrow: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance (GlobeNewswire)
Feb-28-26 09:32AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-26-26 05:35AM	TheStreet Pro: Four Stocks that Will Win Despite Irrational Panic over AI (TipRanks)
Feb-24-26 10:00AM	Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Analysts Boost Profit Forecasts On Two Names. One Is A Data Center Play. (Investor's Business Daily)
Feb-23-26 02:20PM	Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout (Investor's Business Daily)
10:00AM	Loading…
10:00AM	Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-18-26 07:00AM	Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 (GlobeNewswire)
Feb-17-26 06:01PM	Private Capital's Strategic Moves: ECN Capital Corp Exit Impacts Portfolio by -3.57% (GuruFocus.com) +5.98%
07:00AM	Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack Kits (GlobeNewswire)
Feb-04-26 01:07PM	Eye Care Stock Sees New Path After Guidance (Investor's Business Daily)
Feb-03-26 06:28AM	Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? (Zacks) +5.10%
Feb-02-26 07:00AM	Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270-$280 Million, Marking Another Year of Strong Growth (GlobeNewswire) +9.67%
Jan-15-26 01:00PM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
08:55AM	Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength (Zacks)
Dec-09-25 12:56PM	Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong (Investor's Business Daily)
Nov-24-25 07:00AM	Harrow to Present at Two Investor Conferences in December (GlobeNewswire)
Nov-18-25 07:00AM	Harrow Announces Closing of Acquisition of Melt Pharmaceuticals (GlobeNewswire)
Nov-14-25 05:03PM	Private Capital's Strategic Moves: Spotlight on Matthews International Corp (GuruFocus.com) +7.65%
Nov-11-25 02:01PM	Harrow Inc (HROW) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans (GuruFocus.com) +13.47%
Nov-10-25 04:31PM	Harrow: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Harrow Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-27-25 07:00AM	Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 (GlobeNewswire)
Oct-08-25 11:23AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey) -5.14%
Oct-06-25 07:00AM	ImprimisRx Announces Leadership Changes (GlobeNewswire) -7.20%
Sep-26-25 08:57AM	Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? (Benzinga)
07:00AM	Harrow to Acquire Melt Pharmaceuticals (GlobeNewswire)
Sep-25-25 04:05PM	Harrow Launches Harrow Access for All (HAFA) (GlobeNewswire)
Sep-15-25 07:00AM	Harrow Announces Agenda and Speakers for Investor & Analyst Day (GlobeNewswire) +8.63%
Sep-08-25 05:57PM	Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 (GlobeNewswire) +7.52%
08:00AM	Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 (GlobeNewswire)
Sep-02-25 04:07AM	Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea (Insider Monkey)
Aug-26-25 04:15AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Aug-15-25 12:20PM	Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock (Zacks)
10:00AM	Best Momentum Stock to Buy for August 15th (Zacks)
09:55AM	Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet (Zacks)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily) +9.62%
Aug-11-25 05:55PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second-Quarter 2025 Financial Results (GlobeNewswire)
09:23AM	Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-08-25 09:22AM	Harrow Inc (HROW) Q2 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Aug-06-25 07:00AM	Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference (GlobeNewswire)
Aug-04-25 10:00AM	Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) +7.01%
Jul-29-25 07:00AM	Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 (GlobeNewswire)
Jul-21-25 03:34PM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Jul-17-25 07:00AM	Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
07:00AM	Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
Jul-14-25 10:01AM	Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? (Zacks)
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly) +11.35%
Jul-06-25 04:15AM	William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating (Insider Monkey)
Jul-02-25 09:00AM	Are Options Traders Betting on a Big Move in Harrow Stock? (Zacks)
Jun-18-25 07:00AM	Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications (Business Wire)
Jun-09-25 07:00AM	Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals (Business Wire)
May-14-25 10:07AM	Jim Cramer on Harrow, Inc. (HROW) - "Eye Care's a Good Biz - If It Makes Money, Don't Walk Away Pre-Breakout" (Insider Monkey)
07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-10-25 03:03AM	Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
May-08-25 05:10PM	Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Harrow Announces First-Quarter 2025 Financial Results (Business Wire)
09:32AM	Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-07-25 10:28AM	What To Expect From Harrow Inc (HROW) Q1 2025 Earnings (GuruFocus.com)
May-05-25 07:00AM	Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 (Business Wire)
Apr-30-25 07:35AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-29-25 07:35AM	What Recession? I'm Swimming In Dividends (Seeking Alpha)
Apr-24-25 10:00AM	NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) (PR Newswire) +5.20%
Apr-21-25 04:26PM	Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Apr-10-25 07:00AM	Harrow Expands VEVYE Access for All Program to ImprimisRxs Klarity-C Patients (Business Wire) -5.76%
Mar-29-25 04:30PM	Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) (Seeking Alpha)
03:01PM	Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives (GuruFocus.com)
Mar-28-25 02:00PM	Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call (Seeking Alpha) -5.96%
01:39PM	Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (Seeking Alpha)
Mar-27-25 06:45PM	Harrow (HROW) Q4 Earnings and Revenues Top Estimates (Zacks)
04:01PM	Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results (Business Wire)
10:45AM	Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 (Business Wire)
Mar-24-25 07:00AM	Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL (Business Wire) +5.60%
Mar-21-25 10:56PM	What To Expect From Harrow Inc (HROW) Q4 2024 Earnings (GuruFocus.com)
Mar-19-25 05:18PM	Harrow: A Name I Am Accumulating (SeekingAlpha)
Mar-17-25 04:01PM	Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance (Business Wire) +15.69%
07:00AM	Harrow Launches VEVYE Access for All (Business Wire)
Mar-11-25 07:00AM	Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE (Business Wire)
Mar-03-25 07:15AM	Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025 (Business Wire) -8.73%
Feb-07-25 09:40AM	Reddit initiated, Cigna downgraded: Wall Streets top analyst calls (TipRanks)
Jan-27-25 07:30AM	Harrow Partners with Cencora to Launch Harrow Cares Program, Making IHEEZO and TRIESENCE More Accessible and Affordable for Retina Specialists and Their Patients (Business Wire)
Jan-07-25 07:00AM	Harrow Appoints Amir H. Shojaei as Chief Scientific Officer (Business Wire)
Nov-21-24 07:00AM	Harrows ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. (Business Wire)
Nov-20-24 07:00AM	Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery (Business Wire) +6.90%
Nov-15-24 07:00AM	Harrow Announces Participation in Upcoming Investor Conferences (Business Wire) -8.98%
02:06AM	Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... (GuruFocus.com)
Nov-13-24 04:34PM	Harrow Announces Third Quarter 2024 Financial Results (Business Wire) -17.26%
07:16AM	Harrow Inc (HROW) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
07:00AM	Harrow Launches Access and Affordability Program with Price Reductions for Branded Products (Business Wire)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Mar 04 '26	Sale	39.67	138,263	5,485,184	59,428	Mar 05 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '26	Sale	39.15	60,309	2,361,242	63,691	Mar 05 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 27 '26	Sale	54.18	5,000	270,900	65,000	Mar 03 04:05 PM
Opaleye Management Inc.	10% Owner	Jan 06 '26	Sale	53.35	20,000	1,066,914	70,000	Jan 08 04:05 PM
BOLL ANDREW R.	PRESIDENT AND CFO	Dec 12 '25	Option Exercise	3.95	60,000	237,000	837,844	Dec 16 08:50 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Dec 12 '25	Option Exercise	3.95	180,000	711,000	3,066,124	Dec 16 08:48 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Jul 21 '25	Option Exercise	7.87	600,000	4,722,000	3,199,462	Jul 23 09:10 PM
Opaleye Management Inc.	10% Owner	Jun 10 '25	Sale	30.80	15,000	462,033	90,000	Jun 11 04:15 PM
Opaleye Management Inc.	10% Owner	Jun 09 '25	Sale	30.37	15,204	461,794	105,000	Jun 11 04:15 PM
Opaleye Management Inc.	10% Owner	Jun 03 '25	Sale	30.04	3,000	90,116	122,000	Jun 05 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 04 '25	Sale	30.02	1,796	53,907	120,204	Jun 05 04:05 PM
Opaleye Management Inc.	10% Owner	May 12 '25	Sale	25.90	10,000	258,959	130,000	May 14 04:56 PM
Opaleye Management Inc.	10% Owner	May 13 '25	Sale	26.59	5,000	132,945	125,000	May 14 04:56 PM
BOLL ANDREW R.	Chief Financial Officer	Apr 03 '25	Option Exercise	0.00	346,500	0	914,589	Apr 07 09:55 PM
SAHAREK JOHN P.	CEO & President, ImprimisRx	Apr 03 '25	Option Exercise	0.00	277,200	0	576,863	Apr 07 09:54 PM
BAUM MARK L	Chief Executive Officer	Apr 03 '25	Option Exercise	0.00	762,300	0	2,899,825	Apr 07 09:54 PM
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	30.01	5,000	150,055	140,000	Mar 26 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	29.64	5,000	148,200	145,000	Mar 20 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HROW

Harrow Inc

Upgrade your FINVIZ experience